In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GW Pharmaceuticals nets $325.4mm in FOPO

Executive Summary

GW Pharmaceuticals PLC (cannabinoid products) netted $325.4mm in a follow-on public offering of 2.2mm American Depositary Shares (ADS; including full exercise of the over-allotment option represents 26.2mm ordinary shares) at $158 per ADS on the Nasdaq. The company plans to use the offering proceeds to fund US launch activities for Epidiolex (pharmaceutical oral formulation of cannabidiol, approved for the treatment of seizures associated with lennox-gastaut syndrome or Dravet syndrome); pre-launch commercialization activities of the drug in Europe; and further expansion of its manufacturing capability.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies